{"filing":{"accession_number":"0001628280-26-052125","cik":"0001840706","ticker":"SOPH","company_name":"SOPHiA GENETICS SA","form":"6-K","filing_date":"2026-08-04","report_date":"2026-06-30","primary_document":"soph-20260630.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1840706/000162828026052125/soph-20260630.htm"},"events":[{"id":23563,"run_id":21297,"accession_number":"0001628280-26-052125","anchor_item_number":"EX-99.3","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a press release announcing SOPHiA GENETICS' second quarter 2026 financial results, including revenue of $23.3 million (up 27% YoY), net loss of $22.4 million, and adjusted EBITDA loss of $8.8 million. The release includes detailed financial highlights, business metrics, and updated full-year 2026 revenue guidance ($94–$96 million, raised from prior range of $92–$94 million). The exhibit contains interim condensed consolidated financial statements for the three and six months ended June 30, 2026, confirming this is a discrete earnings announcement, not a periodic financial report.","company_name":"SOPHiA GENETICS SA","ticker":"SOPH","filing_date":"2026-08-04","form":"6-K","submitted_at":null,"items":[{"id":23827,"accession_number":"0001628280-26-052125","item_number":"EX-99.3","item_title":"sophiageneticssaex993q22026.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a press release announcing SOPHiA GENETICS' second quarter 2026 financial results, including revenue of $23.3 million (up 27% YoY), net loss of $22.4 million, and adjusted EBITDA loss of $8.8 million. The release includes detailed financial highlights, business metrics, and updated full-year 2026 revenue guidance ($94–$96 million, raised from prior range of $92–$94 million). The exhibit contains interim condensed consolidated financial statements for the three and six months ended June 30, 2026, confirming this is a discrete earnings announcement, not a periodic financial report.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-04T10:47:52.170532+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23825,"accession_number":"0001628280-26-052125","item_number":"EX-99.1","item_title":"soph-20260630_d2.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is an unaudited interim condensed consolidated financial statement for the six months ended June 30, 2026, prepared in accordance with IAS 34 (Interim Financial Reporting). It comprises the standard components of an interim financial report: statements of loss, comprehensive loss, balance sheets, changes in equity, cash flows, and supporting notes. This is a periodic financial report itself, not a discrete event or earnings release announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-04T10:47:52.170532+00:00","company_name":"SOPHiA GENETICS SA","ticker":"SOPH","filing_date":"2026-08-04"},{"id":23826,"accession_number":"0001628280-26-052125","item_number":"EX-99.2","item_title":"sophiageneticssaex992q22026.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is the Management's Discussion and Analysis (MD\u0026A) accompanying interim condensed consolidated financial statements for the six months ended June 30, 2026, prepared under IAS 34 (Interim Financial Reporting). The document explicitly states it should be read \"in conjunction with our interim condensed consolidated financial statements\" (Exhibit 99.1) and references the company's Annual Report on Form 20-F. This is a periodic interim financial report, not a discrete event disclosure. While the exhibit discusses recent strategic partnerships and litigation, these are contextual disclosures within the MD\u0026A framework, not standalone event announcements.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-04T10:47:52.170532+00:00","company_name":"SOPHiA GENETICS SA","ticker":"SOPH","filing_date":"2026-08-04"},{"id":23827,"accession_number":"0001628280-26-052125","item_number":"EX-99.3","item_title":"sophiageneticssaex993q22026.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a press release announcing SOPHiA GENETICS' second quarter 2026 financial results, including revenue of $23.3 million (up 27% YoY), net loss of $22.4 million, and adjusted EBITDA loss of $8.8 million. The release includes detailed financial highlights, business metrics, and updated full-year 2026 revenue guidance ($94–$96 million, raised from prior range of $92–$94 million). The exhibit contains interim condensed consolidated financial statements for the three and six months ended June 30, 2026, confirming this is a discrete earnings announcement, not a periodic financial report.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-04T10:47:52.170532+00:00","company_name":"SOPHiA GENETICS SA","ticker":"SOPH","filing_date":"2026-08-04"}]}